Market Overview

Gritstone Oncology Appoints Experienced Financial Executive, Steve E. Krognes, to its Board of Directors


, Inc., an immuno-oncology company developing tumor-specific
cancer immunotherapies to fight multiple cancer types, today announced
the appointment of Steve E. Krognes to the company's board of directors.
Mr. Krognes, who currently serves as the chief financial officer of
Denali Therapeutics Inc., brings more than 25 years of finance and life
sciences industry experience to Gritstone Oncology, including experience
in investment banking, corporate and operational finance, mergers and
acquisitions and as a board director.

"We are thrilled to welcome Steve to our board of directors as we work
to advance our lead neoantigen immunotherapy, GRANITE-001, toward
clinical trials," said Andrew Allen, M.D., Ph.D., president and chief
executive officer, Gritstone Oncology. "Steve's life sciences industry
experience will be a valuable addition to Gritstone."

Prior to joining Denali Therapeutics, Mr. Krognes served as the chief
financial officer and a member of the executive committee at Genentech.
Mr. Krognes also represented Genentech on the board and executive
committee of the California Life Science Association and served as
chairman of the Genentech Access to Care Foundation. Before Genentech,
Mr. Krognes led the global mergers and acquisitions team at Roche
Holdings in Switzerland. Earlier in his career, Mr. Krognes worked as an
investment banker at Goldman Sachs, a management consultant at McKinsey
& Company and as a venture capitalist. He holds an MBA from Harvard
Business School, a B.S. in economics from the Wharton School of the
University of Pennsylvania and is a second lieutenant in the Royal
Norwegian Air Force.

"I am impressed with the Gritstone team's innovative approach to
developing personalized cancer immunotherapies for patients, and I am
very excited about the opportunity to contribute to the company's
development by joining its board of directors," said Mr. Krognes.

About Gritstone Oncology

Gritstone Oncology is developing tumor-specific cancer immunotherapies
to fight multiple cancer types. The company has built its approach on
two key pillars—a proprietary machine learning-based platform, Gritstone
EDGE™, which provides the powerful ability to predict from a routine
tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented
on a patient's tumor cells; and second, the ability to develop and
manufacture potent immunotherapies utilizing patients' TSNA to drive the
patient's immune system to attack and destroy tumors. Gritstone brings
together distinguished scientific founders, an experienced and diverse
management team, a seasoned and successful board of directors and deep
financial backing from Versant Ventures, The Column Group, Clarus Funds,
Frazier Healthcare Partners, RedMile, Casdin Capital, Lilly Asia
Ventures, Trinitas Capital, GV, Alexandria Venture Investments and Bay
City Capital. More information can be found at
or @gritstoneonc.

View Comments and Join the Discussion!